ATE118041T1 - Dns, die für faktor ix oder analoges protein kodiert. - Google Patents

Dns, die für faktor ix oder analoges protein kodiert.

Info

Publication number
ATE118041T1
ATE118041T1 AT89403065T AT89403065T ATE118041T1 AT E118041 T1 ATE118041 T1 AT E118041T1 AT 89403065 T AT89403065 T AT 89403065T AT 89403065 T AT89403065 T AT 89403065T AT E118041 T1 ATE118041 T1 AT E118041T1
Authority
AT
Austria
Prior art keywords
factor
analogous protein
dna coding
protein
prosequence
Prior art date
Application number
AT89403065T
Other languages
English (en)
Inventor
Pierre Meulien
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE118041T1 publication Critical patent/ATE118041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT89403065T 1988-11-09 1989-11-07 Dns, die für faktor ix oder analoges protein kodiert. ATE118041T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8814635A FR2638643B1 (fr) 1988-11-09 1988-11-09 Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

Publications (1)

Publication Number Publication Date
ATE118041T1 true ATE118041T1 (de) 1995-02-15

Family

ID=9371722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89403065T ATE118041T1 (de) 1988-11-09 1989-11-07 Dns, die für faktor ix oder analoges protein kodiert.

Country Status (7)

Country Link
US (1) US5521070A (de)
EP (1) EP0373012B1 (de)
JP (1) JP2936201B2 (de)
AT (1) ATE118041T1 (de)
CA (1) CA2002540C (de)
DE (1) DE68920980T2 (de)
FR (1) FR2638643B1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69101634T4 (de) * 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EE200200538A (et) * 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
AU2006331501B2 (en) 2005-12-21 2013-09-05 Aptevo Biotherapeutics Llc Method of producing biologically active vitamin K dependent proteins by recombinant methods
EP2423307A1 (de) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IV-Polypeptide und deren Verwendung bei der Behandlung
JP6050927B2 (ja) 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
EP2220230A2 (de) * 2007-11-09 2010-08-25 Isis Pharmaceuticals, Inc. Modulation der expression von faktor 9
SG189790A1 (en) * 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
CA2892038C (en) 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
CN112175088B (zh) 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760025A (en) * 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
AU8339187A (en) * 1986-11-17 1988-06-16 New England Medical Center Hospitals, Inc., The Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins

Also Published As

Publication number Publication date
FR2638643B1 (fr) 1991-04-12
DE68920980D1 (de) 1995-03-16
JPH02265487A (ja) 1990-10-30
FR2638643A1 (fr) 1990-05-11
JP2936201B2 (ja) 1999-08-23
DE68920980T2 (de) 1995-07-06
EP0373012B1 (de) 1995-02-01
US5521070A (en) 1996-05-28
CA2002540C (fr) 2000-04-04
EP0373012A1 (de) 1990-06-13
CA2002540A1 (fr) 1990-05-09

Similar Documents

Publication Publication Date Title
ATE118041T1 (de) Dns, die für faktor ix oder analoges protein kodiert.
DE3684078D1 (de) Reinigung und aktivierung von proteinen aus unloeslichen einschlusskoerpern.
GR3021198T3 (en) Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
ES2053758T3 (es) Una nueva molecula polipeptidica.
PH20343A (en) Cysteline-depleted muteins of biologically active proteins
DE3687763D1 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
ATE142692T1 (de) Herstellung von hämoglobin und analogen davon durch bakterien oder hefen
EP1160327A3 (de) Proteolytische Enzyme und ihre Verwendung in Waschmitteln
NO863458L (no) Undertrykkbare gjaerpromotorer.
DK135488A (da) Il-3-protein, isaer humant il-3, dets fremstilling og anvendelse i farmaceutica, vektor, som koder proteinet, samt celler transformeret med vektoren
GR3005040T3 (de)
EP0246307A4 (de) Durch cys-kodon modifizierte dns.
ATA192895A (de) Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
MX9203879A (es) Muteina de il-6 con cisteina parcialmente suprimida.
ES2058479T3 (es) Compuestos peptidicos.
EP0336779A3 (de) Durch kovalenten Ersatz von Wasserstoffbrücken stabilisierte Polypeptide
CA2006969A1 (en) Polypeptide having human monocyte chemotactic factor activity and a dna encoding said polypeptide
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
DE69120315D1 (de) Rekombinante DNA-Expressionsvektoren und DNA-Zusammensetzungen, die Isopenizillin N-Epimerase-Aktivität kodieren
FI882238A0 (fi) Foerbaettringar i samband med organiska foereningar
PT942978E (pt) Metodos para produzir o complexos promotor da anafase
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
AU525042B2 (en) Ovulation enhancing peptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee